Shares of Celldex Therapeutics continued to rise on Friday, four days after the company said it has begun a pilot study of a treatment for a rare kidney disease called dense deposit disease. Celldex said the first patient was dosed in the study of the disease, which ultimately results in kidney failure for most patients. Celldex has its operations office in Needham and also operates a manufacturing plant in Fall River, among other facilities in the Northeast. Full story for BostonGlobe.com subscribers.
This is a summary. To read the whole story subscribe to BostonGlobe.com
© Copyright 2013 Globe Newspaper Company.
Get the full story with unlimited access to BostonGlobe.com. Just 99¢ for 4 weeks.